ID1: A Potential Drug Target for Neurodegenerative Diseases (G3397)

Target Name: ID1

NCBI ID: G3397

Content of Review Report on ID1 Target / Biomarker

ID1

ID1: A Potential Drug Target for Neurodegenerative Diseases

The protein ID1 (inhibitor of DNA binding 1, dominant negative helix-loop-helix protein) is a key regulator of gene expression and has been identified as a potential drug target in the field of neurodegenerative diseases.ID1 is a member of the helix-loop-helix (HLH) family of proteins, which are known for their ability to form a stable complex with DNA. In this article, we will explore the structure and function of ID1, as well as its potential as a drug target.

Structure and Expression

ID1 is a 21-kDa protein that is expressed in a variety of tissues, including brain, heart, and muscle. It is primarily expressed in the brain and has been shown to localize to specific regions of the brain, including the cerebral cortical spine and the cerebellum.ID1 is highly conserved, with a calculated pI of 6.9 and a predicted localization to the actinin complex, a subcellular structure that is involved in the formation of actin filaments.

Function

ID1 plays a critical role in the regulation of gene expression and has been shown to interact with a wide range of transcription factors, including nuclear factor KLF1, p300, andCREB2. It is well-known for its ability to inhibit the activity of DNA-binding proteins, such as histone-modifying enzymes and transcription factors, which are responsible for the recruitment of DNA to their respective binding sites.

ID1's ability to inhibit DNA binding has led to its potential as a drug target. By inhibiting the activity of DNA-binding proteins, ID1 has been shown to reduce the level of gene expression and potentially lead to the onset of neurodegenerative diseases. Additionally, ID1 has been shown to play a role in the regulation of cellular processes such as cell division, apoptosis, and inflammation.

Drug Intervention

Several drugs have been shown to interact with ID1 and have been investigated as potential treatments for neurodegenerative diseases. One such drug is currently in clinical trials for the treatment of Alzheimer's disease, specifically for the treatment ofID1-mediated neurodegeneration.

Another drug that has been shown to interact with ID1 is the neuroprotective drug, N-Acetylcysteine (NAC), which has been shown to increase the levels of ID1 in brain tissue and improve the expression of ID1 genes. This suggests that NAC may have potential as a treatment for neurodegenerative diseases by increasing the levels of ID1 and improving its expression.

Conclusion

ID1 is a highly conserved protein that plays a critical role in the regulation of gene expression and has been identified as a potential drug target for the treatment of neurodegenerative diseases. Its ability to inhibit the activity of DNA-binding proteins makes it an attractive target for drug intervention, and several drugs that have been shown to interact with ID1 are currently in clinical trials for the treatment of such diseases. Further research is needed to fully understand the role of ID1 in neurodegenerative diseases and to develop effective treatments.

Protein Name: Inhibitor Of DNA Binding 1

Functions: Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity. Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation. Inhibits skeletal muscle and cardiac myocyte differentiation. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer (By similarity)

The "ID1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ID1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets